Major thalassemia. Beta thalassaemia
Conditions
Interventions
Intervention 1: The first group was treated with subcutaneous infusion of 30-50 mg/kg/day deferoxamine during 8-12 hours for at least 5-6 nights a week using a pumpfor at least one year . Intervention
Treatment - Drugs
The first group was treated with subcutaneous infusion of 30-50 mg/kg/day deferoxamine during 8-12 hours for at least 5-6 nights a week using a pumpfor at least one year .
The second group received 20-40 mg/kg/day deferasirox as a single oral dose before the first meafor at least one year l.
The third group was treated with subcutaneous infusion of 30-50 mg/kg/day deferoxamine during 8-12 hours for at least 5-6 nights a week using a pump and 75-100 mg/kg/day oral deferiprone in three divi
Sponsors
Tehran University of Medical Sciences Vice chancellor for research
Eligibility
Sex/Gender
All
Age
10 Years to 40 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: transfusion dependent thalassemia with age over 10 years;cardiac iron load on MRI T2 * Exclusion criteria : severe hepatic disorder; renal disease; history of neutropenia; history of adverse reactions to any of chelators in the past; failure to perform MRI T2 * due to causes such as pacemakers; pregnancy; fear of closed environment
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Srum ferritin, ng/ml. Timepoint: 0 and 12 month later. Method of measurement: RIA. | — |
Secondary
| Measure | Time frame |
|---|---|
| Cardiac Iron Load. Timepoint: 0 and 12 month later. Method of measurement: Cardiac MRI T2*. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactShahla Ansari
Tehran University of Medical Sciences
Outcome results
None listed